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Abstract
Background: Granulocytes and monocytes/macrophages differentiate from common myeloid progenitor cells. Granulocyte
colony-stimulating factor (G-CSF) and CD137 (4-1BB, TNFRSF9) are growth and differentiation factors that induce
granulocyte and macrophage survival and differentiation, respectively. This study describes the influence of G-CSF and
recombinant CD137-Fc protein on myelopoiesis.
Methodology/Principal Findings: Both, G-CSF and CD137 protein support proliferation and survival of murine bone marrow
cells. G-CSF enhances granulocyte numbers while CD137 protein enhances macrophage numbers. Both growth factors
together give rise to more cells than each factor alone. Titration of G-CSF and CD137 protein dose-dependently changes the
granulocyte/macrophage ratio in bone marrow cells. Both factors individually induce proliferation of hematopoietic
progenitor cells (lin
-, c-kit
+) and differentiation to granulocytes and macrophages, respectively. The combination of G-CSF and
CD137 protein further increases proliferation, and results in a higher number of macrophages than CD137 protein alone,and a
lower number of granulocytes than G-CSF alone demonstrating that CD137 protein-induced monocytic differentiation is
dominant over G-CSF-induced granulocytic differentiation. CD137 protein induces monocytic differentiation even in early
hematopoietic progenitor cells, the common myeloid progenitors and the granulocyte macrophage progenitors.
Conclusions/Significance: This study confirms earlier data on the regulation of myelopoiesis by CD137 receptor - ligand
interaction, and extends them by demonstrating the restriction of this growth promoting influence to the monocytic
lineage.
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Introduction
Granulocytes are essential cells of the innate immune system. As
neutrophil and eosinophil granulocytes they form the first defense
line against bacteria and multicellular parasites, respectively.
Through release of their cytotoxic and inflammatory mediators
granulocytes participate in the elimination of pathogens, recruit-
ment of additional immune cells and perpetuation of the
inflammatory reaction [1]. The activity of granulocytes is partly
regulated via their life span which is short under normal
conditions. Neutrophils, which constitute about 95% of all
granulocytes, have a half life of a just few hours in circulation.
At sites of inflammation proinflammatory cytokines such as G-
CSF, granulocyte macrophage colony-stimulating factor (GM-
CSF), tumor necrosis factor (TNF) and interferon (IFN)-c extend
the life span of granulocytes by preventing apoptosis [2,3].
Numbers of granulocytes can also be increased by enhancing the
proliferation rate of hematopoietic progenitor cells and their
differentiation rate to granulocytes. G-CSF is the single most
important factor for inducing the generation of new granulocytes
from bone marrow. G-CSF is also used to treat neutropenia
induced by cancer chemo or radiation therapy [4].
CD137, a member of the TNF receptor family, can be
expressed by several types of hematopoietic cells, and is involved
in the regulation of multiple and diverse types of immune
responses [5,6]. CD137 ligand is expressed as a transmembrane
molecule on the surface of antigen presenting cells and it too
delivers signals into APC [7,8]. Signaling of CD137 ligand
induced by recombinant CD137 protein or anti-CD137 ligand
antibodies enhances B cell proliferation, and activation, survival
and migration of monocytes [9–16]. CD137 ligand agonists also
induce differentiation of peripheral human monocytes to mature
dendritic cells (DCs) [17,18] as well as DC maturation [19–21].
CD137 and its ligand not only influence mature immune cells
but also play a role in hematopoiesis. Expression of CD137 and its
ligand have been found in the bone marrow [22–24], but different
studies report different conclusions of the functions of the CD137
receptor/ligand system in the bone marrow and in hematopoiesis.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15565While some studies report an inhibitory effect of CD137 ligand
signaling on myelopoiesis [22,24] others find that the CD137
receptor/ligand system induces proliferation of hematopoietic
progenitor cells, colony formation of colony-forming unit (CFU)
granulocyte/macrophage (CFU-GM) and CFU macrophage
(CFU-M), and myelopoiesis resulting the generation of monocytes
and macrophages [23,25].
The other myeloid cell type besides monocytes/macrophages
that originate from CFU-GM are granulocytes. Based on the
enhancing effects of CD137 on other myeloid cells and its role in
regulating survival and apoptosis of mature granulocytes [26] we
aimed to determine how CD137 might influence the generation of
granulocytes.
We find that treatment of total murine bone marrow cells with
recombinant CD137 protein enhances the percentage of myeloid
cells except that of granulocytes. G-CSF and CD137 protein work
together in stimulating cell proliferation and survival. The
underlying mechanisms are (1) a cell type-specific promotion of
cell survival by G-CSF and CD137 protein, and (2) the induction
of monocytic rather than granulocytic differentiation of early
hematopoietic progenitor cells by CD137 protein.
Materials and Methods
Mice
Female BALB/c mice between 8 and 16 weeks of age were used
as a source of bone marrow cells. Animals were specific pathogen
free, and kept with free access to food and water in the animal care
facility at the National University of Singapore under the
institutional guidelines for usage of experimental animals under
protocol 078-06.
Isolation of bone marrow CD11b
+, Ly6G
+ cells, lin
-, c-kit
+
cells, CMP and GMP
The femur bones of BALB/c mice were dissected and the bone
marrow was flushed out with phosphate-buffered saline (PBS),
2 mM EDTA by using a 10 ml syringe and 27G needle. Total
bone marrow cells were passed through 30 mm filter (Miltenyi
Biotec, Germany), washed with PBS, 2 mM EDTA and
resuspended in RPMI1640 (Sigma), 10% fetal bovine serum (FBS).
The CD11b
+, Ly6G
+ cells were isolated by immunomagnetic
separation (MACS) of CD11b
+ cells and followed by fluorescent
activated cell sorting (FACS) of Ly6G
+ cells. Briefly, the fresh bone
marrow cells were incubated with anti-CD11b microbeads
(Miltenyi) for 20 min. The cell suspension was passed through
the LS column (Miltenyi) in strong magnetic field. The CD11b
+
cells were retained in the column. After three washes, the column
was removed from magnetic filed and CD11b
+ cells were flushed
out. The cells were stained with FITC-Ly6G and PE-CD11b Abs
and the CD11b
+, Ly6G
+ cells were sorted by FACS on MoFlo
XDP cell sorter (Beckman Coulter, CA, USA).
The lin
-, c-kit
+ cells were enriched from bone marrow cells by
two steps MACS, with depletion of mature cells with lineage
markers followed by selection of CD117
+ (c-kit) cells, as described
previously [23]. The enriched cells were stained with Pacific blue-
conjugated anti-mouse CD34, PE-conjugated anti-mouse CD117,
PerCP-Cy5.5-conjugated anti-mouse CD16/32, and biotinylated
lineage Abs followed by FITC-conjugated Extravidin, and then
were subjected to FACS sorting on MoFlo XDP cell sorter
(Beckman Coulter). The lin
-, c-kit
+, CD34
+, CD16/32
low popu-
lation was collected as common myeloid progenitors (CMP) and
the lin
-, c-kit
+, CD34
+, CD16/32
high population was collected as
granulocyte-macrophage progenitors (GMP).
Bone marrow cells, CD11b
+, Ly6G
+ cells, lin
-, c-ckit
+ cells,
CMPs and GMPs were cultured in RPMI1640 (Sigma) supple-
mented with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin.
Recombinant proteins and cytokines
Recombinant human CD137-Fc protein was purified from
supernatants of stable transfected CHO cells by protein G
sepharose, as described previously [27]. The endotoxin concen-
tration in the CD137-Fc protein is 55 IU/mg. Human IgG1 Fc
protein was purchased from Accurate Chemical and Scientific
Corporation (Westbury, NY, USA). Recombinant mouse G-CSF
was purchased from Peprotech (Rocky Hill, NJ, USA).
Antibodies and flow cytometry
FITC-conjugated anti-mouse Ly-6G (clone 1A8), PE-conjugat-
ed anti-mouse Gr-1 (clone RB6-8C5), CD11b (clone M1/70),
CD14 (clone Sa2-8), F4/80 (clone BM8), CD137 ligand (clone
TKS-1), APC-conjugated anti-mouse CD115 (clone AFS98),
Pacific blue-conjugated anti-mouse CD34 (clone RAM34),
PerCP-Cy5.5-conjugated anti-mouse CD16/32 (clone 93) anti-
bodies and respective isotype controls (rat IgG2a, rat IgG2b), and
PE-conjugated hamster anti-mouse CD137 (clone 17B5) and its
isotype control (Golden Syrian hamster IgG) were purchased from
eBioscience (San Diego, CA). PE-conjugated anti-mouse CD117
(clone 3C1) and cocktail of biotinylated anti-mouse lineage
markers were obtained from Miltenyi (Germany). FITC-conju-
gated Extravidin was purchased from Sigma (MO, USA). FITC-
conjugated anti-mouse MPO (clone 8F4) and its isotype mouse
IgG1 were obtained from Hycult biotech (Netherlands).
For cell surface staining, the Fc receptors were first blocked by
FcR blocking reagent (Miltenyi, Germany) and incubated with Ag-
specific Abs for 30 min at 4uC. For intracellular staining, the
manufacture instructions of the Fixation/Permeabilization kit
from BD Biosciences (NJ, USA) were followed. The nonspecific
staining was controlled by isotype-matched antibodies.
Flow cytometry was performed either on a FACSCalibur (BD
Biosciences) with CellQuest data acquisition and analysis software, or
on a Cyan flow cytometer (Beckman Coulter) with Summit software.
Cell count
Manual cell count. Cells were harvested after incubation
with 10 mM EDTA for 10 min. Cells were centrifuged and
resuspended in PBS. The numbers of viable cells were assessed by
0.4% Trypan blue (Sigma) staining and counted by using a
Neubauer haemocytometer.
Cell count by flow cytometry. Cell samples were stained
with 0.5 mg/ml 7-AAD for 15 min at room temperature in the
dark and were resuspended in 450 ml PBS. 50 ml of Sphero
AccuCount Blank Particles (about 50,000 beads per 50 ml),
(ACBP-100-10, Spherotech, IL, USA) were added to the
suspension and mixed well. Samples were analyzed by flow
cytometry with CyAn
TM ADP Analyzer (Beckman Coulter). 7-
AAD negative cells were gated as live cells. The population of
beads and target cells were gated separately on the forward/side
scatter plot based on different sizes. The number of cells in each
samples was calculated by the formula: Number of cells in sample
= (Number events of test sample x Number of beads)/Number of
events of beads.
Proliferation assay
Cell proliferation was determined by
3H-thymidine incorpora-
tion. Cells were pulsed with 0.5 mCi of
3H-thymidine (PerkinEl-
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were then harvested onto a Packard Unifilter Plate using a
MicroMate 196 Cell Harvester and counted using a TopCount
Microplate Scintillation Counter (Packard Instruments, Meriden,
CT).
Esterase stain
2–5610
6 cells were smeared onto glass slides. Esterase stain was
performed successively with the a-Naphyl Acetate Esterase kit
(Sigma) for non-specific esterase and the Naphthol AS-D
Chloroacetate Esterase kit (Sigma) for specific esterase following
the manufacturer’s instructions.
Apoptosis assay
Purified bone marrow CD11b
+, Ly6G
+ cells were cultured in
10 mg/ml CD137-Fc precoated wells for 4, 16 and 24 h. Cells
were harvested and labeled with Annexin V-PE and 7-AAD (BD
Bioscience) and analyzed by flow cytometry measuring, with the
compensation for FITC-Ly6G.
Microscopy and photography
Cell morphology and esterase stain were documented by using a
Zeiss Axiovert 40 inverted microscope (Zeiss, Germany) and
Canon PowerShot G6 digital camera.
Statistics
Unless otherwise stated, two tailed unpaired Student’s t-tests
were used to determine statistical significance.
Results
Stimulation of bone marrow cells with CD137 protein
leads to an increase in the percentage of myeloid cell
except of granulocytes
Among freshly isolated bone marrow cells the most prominent
subpopulations were Gr-1
bright granulocytes (46.7%), and CD11b
+
myeloid cells (36.8%). However, most of the myeloid cells seemed
to be immature since CD14 and F4/80, markers for monocytes
and macrophages, were present only on 0.1% and 9.2% of the
cells, respectively. CD11c, a marker for DCs was found only on
2.6% of the cells. 1.2% and 11.6% of the cells were T and B cells,
respectively, as determined via CD3 and CD19 expression
(Figure 1A,B).
For crosslinking of CD137 ligand we used a CD137-Fc fusion
protein consisting of the extracellular domain of CD137 fused to
the constant domain of human IgG1 (Fc) which was immobilized
to the culture dishes. A Fc protein was used as a negative control,
and mock coating with PBS, the solvent for the Fc and CD137-Fc
proteins, was used as a medium control. At day 7, T and B cells
had virtually disappeared (0.4% and 0.6%, respectively), indicat-
ing that lymphocyte survival and/or differentiation is not
supported under these conditions. The percentage of granulocytes
had decreased tremendously and was significantly lower in the
CD137 condition (3.2% vs 9.9%) implying an inhibitory effect of
CD137 protein on granulocyte development. Among the CD137
protein-treated cells, the percentages of cells positive for CD11b,
CD14, F4/80 had increased to 91.4%, 43.9% and 82.2%,
respectively. Among the Fc protein-treated cells, the percentages
of cells positive for CD11b, CD14, F4/80 had also increased
(79.8%, 27.7% and 67.7%, respectively) compared to fresh bone
marrow cells, but to a lesser degree compared to CD137-Fc-
treated cells (Figure 1A,B).
At day 14, granulocytes among the Fc protein-treated cells
remained at 9.6%, whereas they were not detectable (0.7%)
among the CD137 protein-treated cells (Figure 1A,B). Among the
CD137 protein-treated cells the percentages of CD11b
+, CD14
+
and F4/80
+ population had further increased to 95.8%, 64.2%
and 94.6%, respectively. The percentage of DCs as detected by
CD11c staining had increased from 2.6% to 21.8%. In contrast,
among the Fc protein-treated cells the CD11b
+, CD14
+, F4/80
+
populations were declined substantially. The Fc control protein
was not able to support DC survival or differentiation
(Figure 1A,B). Overall cell survival rate for Fc- and CD137-Fc-
treated bone marrow cells were 3.2% and 12.0%, respectively, for
day 7, and 0.4% and 9.3%, respectively, for day 14 (Figure 1B).
The CD137 protein-induced bias towards promoting survival of
monocytic bone marrow cells could also be verified by esterase
staining. Naphthol AS-D chloroacetate, a substrate for specific
esterase, stains cells of the granulocytic lineage purple, and these
cells were predominant in fresh bone marrow cells (Figure 1C).
Also clearly visible in fresh bone marrow cells are the ring-shaped
nuclei, typical for murine neutrophils. After a 7-day exposure to
immobilized CD137 protein, most cells stained black with a-
naphthyl acetate, a substrate for non-specific esterase demonstrat-
ing the shift towards the monocytic lineage. This is supported by
the concomitant increase in cell size and the kidney-shaped nuclei
which are typical of monocytes/macrophages.
CD137 protein does not induce apoptosis of bone
marrow granulocytes
Since a possible explanation for the decrease in the percentage
of granulocytes could be CD137 protein-induced granulocyte
apoptosis, we tested the effects of CD137 protein on granulocyte
survival and death. CD137 protein induced neither cell death in
granulocytes among bone marrow cells (not shown) nor in purified
granulocytes over a 24 h period (Figure 2). However, addition of
G-CSF reduced the rate of granulocyte apoptosis, and the
percentage of early apoptotic cells (Annexin V
+, 7-AAD
2)
dropped from 12.7 to 4.7%, and that for late apoptotic cells
(Annexin V
+, 7-AAD
+) from 4.7 to 2.8% (Figure 2). The
differences in apoptosis rates between the PBS, Fc and CD137-
Fc conditions were not statistically significant among three
independent experiments.
G-CSF and CD137 protein cooperatively induce survival
and proliferation of bone marrow cells
Since CD137 protein supports monocyte but not granulocyte
survival and/or differentiation we investigated the interaction of
CD137 protein with G-CSF, the classical granulocyte growth and
differentiation factor, in regulating bone marrow cell survival,
proliferation and differentiation.
Bone marrow cells were treated with one dose of 10 mg/ml of
immobilized CD137-Fc protein or daily doses of 1 ng/ml G-CSF,
or both. Cells treated with Fc protein or Fc + G-CSF were used as
controls. Both CD137 protein and G-CSF increased cell
proliferation (Figure 3A) and cell numbers (Figure 3B), with
comparable potencies. The combination of CD137 protein and G-
CSF was more potent than either factor alone (Figure 3A,B).
CD137 protein and G-CSF enhance bone marrow
macrophage and granulocyte numbers, respectively
Data in Figure 1 implied that CD137 protein reduces the
percentage of granulocytes. This could indeed be verified by
treating bone marrow cells for 7 days with CD137-Fc protein or
G-CSF or both, and analyzing cell composition by flow cytometry
G-CSF and CD137 Regulate Myeloid Differentiation
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granulocytes and macrophages, respectively. Bone marrow cells
treated with CD137 protein contained a significantly lower
percentage of Gr-1
+ cells than the Fc control condition
(7.261.2% vs 25.463.9%), (Figure 4A). In bone marrow cells
treated with G-CSF 41.566.2% of the cells were Gr-1
+. The
presence of CD137 protein however reduced the G-CSF-mediated
increase in granulocyte percentage to 21.563.6%. The Fc control
protein had no influence on the percentage of Gr-1
+ cells
(40.766.6%), (Figure 4A). Reciprocally, G-CSF reduced the
CD137 protein-mediated increase in the macrophage percentage.
Of CD137-Fc-treated bone marrow cells 65.465.4% and
Figure 2. CD137 protein does not induce apoptosis of granulocytes. CD11b
+ cells were enriched from bone marrow by MACS, and labeled
with CD11b-PE and Ly6G-FITC Ab. 3610
5 FACS-sorted CD11b
+, Ly6G
+ cells at a density of 6610
5 cells/ml were cultured on plates coated with 10 mg/
ml Fc or CD137-Fc protein for 24 h. Cells were stained with Annexin V-PE and 7-AAD and analyzed by flow cytometry with compensation of FITC
channel. PBS: Medium control. This figure is a representative of three independent experiments.
doi:10.1371/journal.pone.0015565.g002
Figure 1. Recombinant CD137 protein enhances the percentage of monocytic cells but not that of granulocytes. (A) Bone marrow cells
were analyzed immediately after isolation (day 0) for cell surface marker expression by flow cytometry, or 6610
6 bone marrow cells were cultured in
T25 flasks coated with 1 ml of 10 mg/ml of Fc or CD137-Fc protein and analyzed on days 7 and 14. Black line: Isotype. Gray, filled curve: Marker-
specific antibody. (B) Depicted are absolute numbers of live cells (left column) and percentages (right column) of data in (A) for indicated
subpopulations at days 0, 7 and 14. (C) Fresh murine bone marrow cells, or cells which were cultured on plates coated with 10 mg/ml CD137-Fc
protein for 7 days, smeared on glass slides, fixed with citrate-acetone-formaldehyde solution, and stained for non-specific esterase (black,
macrophages) and for specific esterase (purple, granulocytes). Slides were counterstained with hematoxylin and mounted with cover slips.
Magnification: 6630. Scale bar: 25 mm. These data are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0015565.g001
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number dropped to 36.165.3% and 50.664.2%, respectively,
when G-CSF was added (Figure 4B).
The effects of G-CSF and CD137 protein on the composition of
the cell population are dose-dependent. Bone marrow cells were
grown for 7 days on plates coated with a fixed concentration
(10 mg/ml) of CD137-Fc or Fc protein, and G-CSF was added
daily at 0, 1, 10 or 100 ng/ml. In the absence of G-CSF two thirds
of the cells expressed CD14 and/or F4/80 and 10% expressed Gr-
1. With increasing concentrations of G-CSF the percentage of
granulocytes increased and the percentage macrophages decreased
(Figure 4C). However, G-CSF at 100 ng/ml did not induce more
granulocytes than at 10 ng/ml, indicating a saturation point
between these two concentrations. In a parallel experiment G-CSF
was kept constant at 10 ng/ml, and the coating concentrations of
CD137-Fc and Fc proteins were varied from 0, 5, 10 and 20 mg/
ml. In the absence of CD137 protein 58.2% expressed Gr-1 and
5.8% expressed CD14 (Figure 4D). Increasing concentrations of
CD137 protein reduced the percentage of granulocytes and
increased correspondingly the percentage of macrophages. The
pattern was similar for F4/80 (Figure 4D).
The dose-dependent shift in the granulocyte/macrophage ratio
by the titration of G-CSF and CD137 protein was predominantly
due to a cell-type-specific survival effect that increased the total
number of granulocytes and macrophages, respectively. Similar to
the relative composition of cells, G-CSF treatment resulted in a
high absolute number of Gr-1
+ granulocytes and a low absolute
number of F4/80
+ macrophages while CD137 had the opposite
effect (Figure 4E). But the absolute number of granulocytes was
not affected when bone marrow cells were treated with CD137
protein in addition to G-CSF (Figure 4E). Similarly, the absolute
number of F4/80
+ macrophages was not significantly reduced
when cells were treated with G-CSF in addition to CD137 protein.
CD137 protein acts on early myeloid progenitor cells
As shown above the CD137 protein-induced increase in the
macrophage/granulocyte ratio is at least in part due to its effects
on mature bone marrow cells. But CD137 ligand signaling has also
been shown to influence proliferation and differentiation of
hematopoietic progenitor cells [23–25]. Bone marrow cells that
were depleted of cells expressing markers of mature cells (lin
2) and
enriched for c-kit, the receptor for stem cell factor, proliferated,
formed colonies and differentiated to macrophages [25]. There-
fore, the increased macrophage/granulocyte ratio might also be
due to influences of the CD137 protein and G-CSF on
hematopoietic progenitor cell differentiation.
As expected, G-CSF induced granulocytic differentiation in
lin
2, c-kit
+ cells whereas CD137-Fc protein induced monocytic
differentiation. An predominant induction of granulocytic differ-
entiation by G-CSF has been shown before [28,29]. When both
factors, G-CSF and CD137-Fc were added together the same high
percentage of monocytic cells (CD11b
+, Ly-6G
2) were obtained as
with CD137 protein alone. Although the addition of G-CSF to
CD137 protein-stimulated cells increased the percentage of
granulocytes (CD11b
+, Ly6G
+) from 8.6% to 18.5%, it was still
much lower than that with G-CSF alone (71.8%), (Figure 5A).
Figure 3. G-CSF and CD137 protein induce proliferation and survival of bone marrow cells. Murine bone marrow cells at a density of 10
6
cells/ml were cultured for 7 days with respective treatment. 10 mg/ml of Fc or CD137-Fc protein were pre-coated on the plates. (A) Proliferation assay:
1 ng/ml of G-CSF was added daily to indicated wells. Cells (10
5/condition) were labeled for the last 24 h with 0.5 mCi
3H-thymidine, and the rate of
proliferation was determined with a scintillation counter (Packard, Meriden, CT). Depicted are means 6 standard deviations of triplicate
measurements. (B) Cell count: 10 ng/ml of G-CSF was added daily to indicated wells. Cells (2610
6/condition) were harvested on day 7, and cell count
was determined by trypan blue staining of 4 representative microscopic fields. Depicted are means 6 standard errors of seven independent
experiments. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0015565.g003
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15565This indicated that, in the presence of CD137 protein, G-CSF had
less influence on the differentiation of the progenitor cells, while
CD137 protein was dominant and more potent in inducing
monocytic differentiation.
The dominance of CD137 protein in inducing monocytic
differentiation was also evident from the absolute cell numbers
since drastically fewer granulocytes were present when CD137
protein was added to G-CSF-treated cells (47,800 vs 176,600),
(Figure 5B). However, this was not a mutual two-way competition,
because both factors together gave rise to more monocytic
cells than CD137 protein alone (130,700 vs 59,400), (Figure 5B).
This means that G-CSF contributed to enhanced proliferation
and survival of progenitor cells but CD137 protein redi-
rected differentiation from the granulocytic to the monocytic
lineage. These results were confirmed by measuring expression of
myeloperoxidase (MPO) and CD115 (M-CSF receptor), another
set of granulocytic versus monocytic markers, respectively
(Figure 5C,D).
CD137 protein is able to induce monocytic differentiation in
even more primitive hematopoietic progenitor cells. Common
myeloid progenitors (CMP: lin
2, c-kit
+, CD34
+, CD16/32
low) and
granulocyte macrophage progenitors (GMP: lin
2, c-kit
+, CD34
+,
CD16/32
high) were isolated from lin
2, c-kit
+ cells by cell sorting
(Figure 6A). When the cells were stimulated with immobilized
CD137-Fc protein they showed an increased adherence and a
change to macrophage morphology (Figure 6B). Also, the
monocytic cell population (CD11b
+, Ly6G
2) was increased but
not the granulocytic cell population (CD11b
+, Ly6G
+), (Figure 6C).
These data together with published reports [7,8,11,12] confirm
CD137 as a potent monocytic growth and differentiation factor.
Figure 5. Dominance of CD137 protein-induced monocytic differentiation. 5610
5 lin
2, c-kit
+ cells at a density of 5610
5 cells/ml were
cultured on plates that had been coated with 10 mg/ml of Fc or CD137-Fc protein or that were not coated (PBS, medium control). Where indicated, G-
CSF was added daily at 10 ng/ml. The percentages (A) and absolute numbers (B) of CD11b
+, Ly6G
2 and CD11b
+, Ly6G
+ cells, and the percentages (C)
and absolute numbers (D) of CD115
+, MPO
2 and CD115
2, MPO
+ cells were determined by flow cytometry on day 7. (A) and (C) are representatives of
five and two experiments, respectively, (B) and (D) are depicted as means 6 standard errors of five and two independent experiments, respectively.
*p ,0.05.
doi:10.1371/journal.pone.0015565.g005
Figure 4. Effect of G-CSF and CD137 protein on granulocyte and macrophages numbers. 2610
6 murine bone marrow cells at a density of
10
6 cells/ml were cultured for 7 days on plates that had been coated with 10 mg/ml of Fc or CD137-Fc protein. Where indicated, G-CSF was added
daily at 10 ng/ml or other stated concentrations. The percentages of Gr-1
+ cells (A) and CD14
+, F4/80
+ cells (B), as well as absolute cell numbers (E),
determined by flow cytometry on day 7, are depicted as means 6 standard errors of 7 independent experiments. Dose responses of the combination
of G-CSF and CD137 protein: Cells were treated with a fixed concentration of CD137-Fc at 10 mg/ml and varying the concentration of G-CSF at 0, 1, 10,
or 100 ng/ml (C); or a fixed concentration of G-CSF at 10 ng/ml and varying the concentration of CD137-Fc at 0, 5, 10, or 20 mg/ml (D), and flow
cytometry was performed for Gr-1, CD14 and F4/80 on day 7. These data are representative of two experiments with similar results. Statistical
significance was determined by two tailed, paired Student’s t-test. * p,0.05; ** p,0.01; n.s. not significant.
doi:10.1371/journal.pone.0015565.g004
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CD137 ligand signaling has been shown to regulate multiple
activities of myeloid cells. It induces activation of human and
murine monocytes and macrophages, monocyte migration,
survival and even proliferation. Further, it induces human
monocyte to DC differentiation and maturation of immature
DCs [8]. Also, the proliferation and differentiation of hematopoi-
etic progenitor cells is regulated by CD137 ligand signals although
there are conflicting data on its precise effects on hematopoietic
progenitor cells [24,25].
Given the numerous influences of CD137 ligand signals on
monocytes, macrophages and DCs we hypothesized that the
biology of granulocytes, another type of myeloid cells, may also be
affected. Indeed, that turned out to be the case. However, contrary
to monocytic cells, the percentage of granulocytes among bone
marrow cells was reduced after treatment with recombinant
CD137 protein.
The reduced percentage of granulocytes among total bone
marrow cells could be due to three potential mechanisms: (1)
induction of cell death in granulocytes, (2) prolongation of
monocyte survival, and (3) skewing of differentiation of hemato-
poietic progenitor cells towards the monocytic lineage. Induction
of granulocyte cell death could be ruled out but prolongation of
macrophage survival and enhanced differentiation of progenitor
cells to macrophages both contributed to the increased number of
monocytic cells.
This means that CD137 ligand signaling does not affect
granulocytes directly as is the case for hematopoietic progenitor
cells and monocytic cells, at least not in the murine system. But the
reduced percentage of granulocytes upon treatment with by
CD137 protein was a result of the selective growth stimulus for
monocytic cells. In line with this finding is that there is no evidence
of CD137 ligand expression on murine granulocytes, and that
addition of G-CSF, the prototypic granulocyte growth factor,
raised the percentage of granulocytes among total bone marrow
cells. Adding G-CSF and CD137 protein together resulted in
significantly more cells after a 7-day culture period than either
factor alone. The fact that the combination almost had an additive
effect on the number of live bone marrow cells indicates that each
factor may have promoted survival of distinct subpopulations.
As described above the increased number of monocytic cells
among total bone marrow cells resulted from an increased survival
of mature cells and from an increased monocytic differentiation of
progenitor cells. The opposing effects of G-CSF and CD137
protein in reducing or enhancing the macrophage/granulocyte
ratio among total bone marrow cells was not observed for
hematopoietic progenitor cells indicating that the increased
number of monocytic cells among total bone marrow cells resulted
mainly from promoting survival of mature granulocytes and
macrophages, respectively. Both G-CSF and CD137 protein were
able to induce proliferation of hematopoietic progenitor cells and
to induce granulocytic and monocytic differentiation, respectively.
The combination of G-CSF and CD137 protein generated
significantly (p,0.05) more cells during a 7-day culture period
than either factor alone but the majority of these cells were of the
monocytic lineage based on the CD11b
+, Ly6G
2, and the
CD115
+, MPO
2 phenotype. This means that both factors
contributed to an enhanced hematopoietic progenitor cell
proliferation but CD137 protein was dominant over G-CSF in
inducing monocytic differentiation in the newly emerging cells.
A pathological situation where the hematopoietic activities of
CD137 may play a role could be after injuries, especially burns.
Thermal injuries often lead to monocytosis that is accompanied by
neutropenia, due to a shift of progenitor differentiation away from
granulocytic towards monocytic differentiation [30,31]. The
activities of CD137 protein identified in this study would be
compatible with such a notion.
G-CSF is being used therapeutically for treatment of neutro-
penia [32]. The combination of G-CSF and CD137 ligand
agonists, especially at varying concentrations may allow a precise
fine-tuning of myelopoiesis, depending on whether more granu-
locytes or more macrophages are required for a specific
therapeutic setting.
The above described enhancement of monocytic cell numbers is
likely mediated by signaling through CD137 ligand (reverse
signaling) on progenitor cells inducing monocytic differentiation.
In mature monocytes/macrophages CD137 ligand signaling
induces release of M-CSF, the classical monocyte growth factor
and thereby greatly extends the survival of these cells [12]. In
addition, CD137 ligand signaling induces monocyte growth,
proliferation and endomitosis [11,14]. However, the CD137
receptor/ligand system may also bias myeloid cell composition
towards macrophages, via forward signaling. In the human system,
CD137 can be expressed on mature granulocytes in certain
physiological and/or pathological conditions and signaling
through CD137 has been shown to inhibit granulocyte survival
[26]. On human eosinophil granulocytes CD137 expression is
inducible by an unidentified T cell-derived factor, and crosslinking
of CD137 overrides the pro-survival effects of GM-CSF and IL-5
[33]. Similarly, human neutrophil granulocytes express CD137
constitutively, and crosslinking of CD137 overrides the pro-
survival effects of GM-CSF and induces apoptosis [34]. However,
we could not detect CD137 expression on murine granulocytes
(not shown). This could mean that the monocytic/granulocytic cell
ratio in the murine system is mainly controlled by the
differentiation of progenitor cells.
The CD137 receptor/ligand system has been shown to mediate
monocyte proliferation and endomitosis [11,19–21], DC differen-
tiation [17,18] and maturation [19–21]. Also, CD137 ligand
signaling has been found to regulate proliferation and differenti-
ation of hematopoietic progenitor cells [23–25]. The data of the
present study on the interactions of G-CSF and CD137 on total
bone marrow cells and bone marrow progenitor cells add to the
growing recognition that CD137 and its ligand regulate multiple
aspects of hematopoiesis, in particular of myelopoiesis.
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Figure 6. CD137 protein induces monocytic differentiation in early myeloid progenitor cells. (A) Lin
2, c-kit
+ cells (boxed area of left
panel) were sorted for CD34
+, CD16/32
high (GMP) and CD34
+, CD16/32
low (CMP) cells (right panel). (B) 5610
4 CMP or GMP at a density of 2.5610
5
cells/ml were cultured for 7 days on plates that had been coated with 10 mg/ml of Fc or CD137-Fc protein or that were not coated (PBS, medium
control). Photographs were taken on day 7 at magnification of 6200. Scale bar=50 mm. Please note that the small round particles are cell debris as
evidenced by their small size and the holes in the membranes. (C) The percentages of CD11b
+, Ly6G
2 and CD11b
+, Ly6G
+ cells of (B) were determined
by flow cytometry.
doi:10.1371/journal.pone.0015565.g006
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